Shares of argenx (ARGX) rose after the company announced the FDA approval of Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (‘CIDP’). The product label is broad ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange, but new ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune disease that can cause severe numbness, weakness and disability. In a recent interview hosted by Sanofi, Dr. Jeffrey ...